MARASCA, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.758
EU - Europa 8.182
AS - Asia 1.988
SA - Sud America 61
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 17
AF - Africa 7
Totale 30.031
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.694
GB - Regno Unito 3.719
IT - Italia 1.266
SE - Svezia 1.064
CN - Cina 776
DE - Germania 665
HK - Hong Kong 589
UA - Ucraina 469
TR - Turchia 365
FI - Finlandia 312
BG - Bulgaria 205
FR - Francia 148
IN - India 63
RU - Federazione Russa 62
VN - Vietnam 59
IE - Irlanda 50
BE - Belgio 46
CA - Canada 44
SG - Singapore 43
BR - Brasile 35
NL - Olanda 31
MY - Malesia 25
LT - Lituania 24
CZ - Repubblica Ceca 21
IR - Iran 20
BZ - Belize 19
ES - Italia 18
AU - Australia 16
EU - Europa 15
JP - Giappone 15
CL - Cile 14
RO - Romania 14
PL - Polonia 9
SI - Slovenia 8
SK - Slovacchia (Repubblica Slovacca) 7
GR - Grecia 6
AT - Austria 5
CH - Svizzera 5
CO - Colombia 5
DK - Danimarca 5
ID - Indonesia 5
KR - Corea 5
MK - Macedonia 5
AR - Argentina 4
LK - Sri Lanka 4
PK - Pakistan 4
PT - Portogallo 4
PH - Filippine 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
DZ - Algeria 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
IQ - Iraq 2
LV - Lettonia 2
MD - Moldavia 2
PE - Perù 2
RS - Serbia 2
A1 - Anonimo 1
AM - Armenia 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
EE - Estonia 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
MA - Marocco 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 30.031
Salva come PNG Salva come JPEG
Città #
Fairfield 3.247
Southend 3.187
Woodbridge 1.877
Ashburn 1.659
Houston 1.473
Chandler 1.447
Seattle 1.241
Ann Arbor 1.118
Wilmington 1.043
Cambridge 1.016
Jacksonville 970
Dearborn 837
Nyköping 746
Hong Kong 578
Modena 389
Beijing 305
San Diego 300
Princeton 247
New York 232
Izmir 227
Sofia 203
Eugene 189
Helsinki 144
London 117
Fremont 110
Bremen 90
Redwood City 79
Milan 74
Boardman 60
Des Moines 60
Dong Ket 57
San Jose 52
Rome 50
Bologna 49
Falls Church 49
Dublin 46
Brussels 45
Hefei 43
Norwalk 43
Shanghai 34
Kunming 33
Kilburn 31
Nanjing 29
Chicago 25
Philadelphia 25
Phoenix 25
Albuquerque 24
Frankfurt am Main 24
San Mateo 24
Toronto 24
Las Vegas 21
Guangzhou 20
Belize City 19
Chiswick 19
Dallas 19
Leawood 19
Parma 19
Verona 18
Jinan 16
Hounslow 15
Reggio Emilia 14
Washington 14
Ottawa 13
Perugia 13
Rimini 13
Saint Petersburg 13
Caltanissetta 12
Paris 12
San Francisco 12
Segrate 12
Auburn Hills 11
Saint Louis 11
Florence 10
Fuzhou 10
Los Angeles 10
Prescot 10
Romainville 10
Tulare 10
Acton 9
Indiana 9
Palermo 9
Ravenna 9
San Giuliano Milanese 9
Zhengzhou 9
Bangalore 8
Castelnuovo Rangone 8
Columbus 8
Dongguan 8
Islington 8
Madrid 8
Wuhan 8
Ardabil 7
Atlanta 7
Bari 7
Brno 7
Grafing 7
Hebei 7
Monreale 7
Shenyang 7
Southwark 7
Totale 24.565
Salva come PNG Salva come JPEG
Nome #
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 453
Monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation 398
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors 273
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 272
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 251
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 239
Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. 236
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia 235
NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms 234
Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study 233
Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis 220
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia 219
A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. 218
The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi 209
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 205
Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study 203
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide 201
Atraumatic splenic rupture in patients with myelodysplastic syndromes: Report of a case occurred during treatment with 5-azacitidine and review of the literature. 201
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia 195
May the indirect effects of CIHHV-6 in transplant patients be exerted through the reactivation of the viral replicative machinery? 194
Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma 193
Mucorales-specific T cells in patients with hematologic malignancies 193
BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy. 189
An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells? 189
Antineoplastic effects of liposomal siRNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma 186
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL 186
The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes 185
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib 184
The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign 183
The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. 182
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 182
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 182
Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo 181
Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia 181
Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6 180
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile on leukemic cells. 180
Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis 179
ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia 179
Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma 178
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma 178
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 178
The genetics of nodal marginal zone lymphoma 178
Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status 177
Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis 177
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. 177
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 176
Randomized phase 2 study: Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM 174
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. 173
Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation 172
Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. 171
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 171
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 171
Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia 170
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study 170
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells 168
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 168
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 167
Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene 166
Peripheral lymphadenopathy: role of excisional biopsy in differential diagnosis based on a five-year experience. 165
Chronic myeloid leukemia with thrombocythemic onset may be associated with different BCR/ABL variant transcripts 165
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. 165
Human Herpes virus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction 165
Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. 164
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 164
Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout Tie-2 receptor engagement 163
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 162
Differences among young adults, adults and elderly chronic myeloid leukemia patients 162
Immunoglobulin mutational status detected through single-round amplification of partial VH region, represents a good prognostic marker for the clinical outcome in chronic lymphocytic leukemia 162
Lack of confirmation of an association between HTLV-I infection and myelodysplastic syndrome 161
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 161
Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status 161
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 160
Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL 160
Severe anemia in a patient with multiple sclerosis treated with natalizumab 159
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 157
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 156
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. 156
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature 155
Bone marrow failure associated with human herpesvirus 8 infection after transplantation 154
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 154
BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab 154
Human herpesvirus-6 genome in acute lymphoblastic leukemia: Evidence against an etiologic relationship 154
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival 152
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 149
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment 149
BCR-ABL rearrangement is not detectable in essential thrombocythemia. 149
Acute myeloid leukemia in patients living with HIV infection: Several questions, fewer answers 149
Expression of cell-homologous genes of human herpesvirus-8 in human immunodeficiency virus-negative lymphoproliferative diseases 148
Polymerase chain reaction detection of human herpesvirus 8 sequences in primary central nervous system lymphomas 147
HHV-8-associated primary cerebral B-cell lymphoma in HIV-negative patient after long-term steroids 147
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 147
Missense mutations in the PML/RAR alpha ligand binding domain in ATRA-resistant As2O3 sensitive relapsed acute promyelocytic leukemia 147
Lenalidomide in chronic lymphocytic leukemia: The present and future in the era of tyrosine kinase inhibitors 147
Chronic/relapsing lymphadenopathy associated with HHV-6B infection: a new benign clinico-pathologic entity occurring in immunocompetent individuals 147
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia 147
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 146
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma 146
HUMAN HERPESVIRUS-6 - A SURVEY OF PRESENCE AND DISTRIBUTION OF GENOMIC SEQUENCES IN NORMAL BRAIN AND NEUROGLIAL TUMORS 146
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives 145
Spontaneous adrenal gland haematoma in a patient with antiphospholipid antibodies 144
Totale 18.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.725
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.725
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.795 0 0 0 0 0 0 0 0 0 0 820 975
2019/20207.169 457 289 251 457 718 1.020 1.495 884 655 270 362 311
2020/20215.856 413 272 453 668 850 480 367 674 244 676 397 362
2021/20224.275 197 548 517 206 99 235 259 192 398 307 698 619
2022/20234.255 503 482 325 374 579 570 81 445 488 51 190 167
2023/20242.550 104 162 172 272 562 270 349 452 54 68 85 0
Totale 30.532